ライフサイエンスコーパス: interleukin-10

1 tokines (transforming growth factor beta and interleukin 10).

2 -1, B-cell activating factor, interleukin-6, interleukin-10).

3 m-3; indoleamine 2, 3-dioxygenase (IDO); and interleukin 10.

4 FNgamma and TLR4 signaling, and secretion of interleukin-10.

5 derline significant inverse correlation with interleukin-10.

6 erleukin-6, tumor necrosis factor-alpha, and interleukin-10.

7 air levels of the immunosuppressive cytokine interleukin-10.

8 infection produced interferon-gamma but not interleukin-10.

9 osis, and production of interferon-gamma and interleukin-10.

10 in-8 (124.76 vs 47.48 pg/mL; p = 0.028), and interleukin-10 (104.31 vs 29.72 pg/mL; p < 0.001).

11 ukin-6: 67.50 vs 21.81 pg/mL, p = 0.005; and interleukin-10: 30.98 vs 12.60 pg/mL, p < 0.001).

12 In the absence of interleukin-10, a component of the regulatory immune res

13 hydrocortisone decreased the blood level of interleukin-10, a cytokine centrally involved in the reg

14 Gene expression of interleukin-10, an immune-modulatory cytokine, was signi

15 eukin 4, and M2-associated anti-inflammatory interleukin 10 and arginase I.

16 anti-SLAMF4 and anti-CD3 increased levels of interleukin 10 and interferon gamma secretion by IEL, co

17 kewed T-helper cell response, producing more interleukin 10 and less interferon gamma than cells stim

18 m following cecal ligation and puncture, and interleukin 10 and monocyte chemoattractant protein-1 le

19 (Tregs) and the immunosuppressive cytokines interleukin 10 and transforming growth factor beta is st

20 rotective effect required host production of interleukin-10 and host Tregs.

21 od-stage specific CD4(+) T cells coproducing interleukin-10 and interferon gamma (P = .001), which we

22 for inducible protein-10 in driving systemic interleukin-10 and morbidity and highlighting the potent

23 tly increased the anti-inflammatory cytokine interleukin-10 and reduced proinflammatory cytokines, ty

24 This involves localized production of interleukin-10 and results in suppressed humoral and cel

25 l suppression was attributed to a release of interleukin-10 and S100A12 and increased PD-L1 expressio

26 e is a turtle herpesvirus, (iii) it contains interleukin-10 and semaphorin genes (the first time thes

27 also revealed viral counterparts of cellular interleukin-10 and semaphorin, which have not been descr

28 , induction of the two suppressive cytokines interleukin-10 and transforming growth factor-beta, inhi

29 xpression of mannose receptor-1, Arginase-1, interleukin-10 and transforming growth factor-beta.

30 tumor necrosis factor-alpha, interleukin 6, interleukin 10, and CD206, depended on the type of injur

31 necrosis factor alpha, interleukin 6 (IL-6), interleukin 10, and lipopolysaccharide binding protein w

32 Tumor necrosis factor alpha, interleukin 10, and the expression of miR-155 and miR-10

33 interferon gamma (IFN-gamma), interleukin 2, interleukin 10, and tumor necrosis factor alpha (TNF-alp

34 rleukin 1beta, interleukin 6, interleukin 8, interleukin 10, and tumor necrosis factor alpha release

35 ecreased transforming growth factor-beta and interleukin-10, and (4) CD73(-/-) mice displayed infarct

36 xpress programmed death ligand 1 (PD-L1) and interleukin-10, and directly suppress liver cytotoxic CD

37 consisting of interleukin-6, interleukin-8, interleukin-10, and fractalkine was identified to be the

38 ly loaded with interleukin-6, interleukin-8, interleukin-10, and fractalkine, was significantly highe

39 interleukin-6, tumor necrosis factor alpha, interleukin-10, and interferon-gamma in acute disease.

40 ignificant increase in plasma interleukin-8, interleukin-10, and interleukin-1 receptor antagonist po

41 ion of pericentrin attenuated interleukin-6, interleukin-10, and MCP1 secretion, suggesting that the

42 uce the suppressive cytokines interleukin-6, interleukin-10, and transforming growth factor-beta but

43 tor-alpha, interleukin-6, interleukin-1beta, interleukin-10, and transforming growth factor-beta in b

44 related with decreased expression of CTLA-4, interleukin-10, and transforming growth factor-beta.

45 hey secrete interferon-gamma, interleukin-2, interleukin-10, and tumor necrosis factor.

46 and 3) selective secretion of interleukin-6, interleukin-10, and vascular endothelial growth factor t

47 ial killing, and tumor necrosis factor-alpha/interleukin-10 baseline intracellular cytokine levels.

48 changes in interleukin-6, interleukin-8, and interleukin-10 blood levels.

49 leukin 18) and the antiinflammatory cytokine interleukin 10 but not with decreased systemic levels of

50 Cs, which was dependent on the generation of interleukin 10 by Tregs.

51 ation markers, such as YM-1, arginase-1, and interleukin-10 by activation of mer receptor tyrosine ki

52 erleukin-6, tumor necrosis factor-alpha, and interleukin-10 by lipopolysaccharide-stimulated leukocyt

53 egulatory B-cell-associated surface markers, interleukin-10, chemokine receptors, and immunoglobulin

54 ue of the cellular immunomodulatory cytokine interleukin 10 (cIL-10), which, due to alternative splic

55 tokines that are orthologs of human cellular interleukin 10 (cIL-10).

56 CMV) each encode an ortholog to the cellular interleukin-10 (cIL-10) cytokine: cmvIL-10 and rhcmvIL10

57 Both cytomegalovirus interleukin 10 (cmvIL-10) and Latency-associated cytomeg

58 UL111A encodes cytomegalovirus-encoded human interleukin-10 (cmvIL-10), a homolog of the potent immun

59 ed with a trend toward increased mean plasma interleukin-10 concentrations (5.6 v 7.1 pg/mL; P = .06)

60 repeatedly measured plasma interleukin-6 and interleukin-10 concentrations using cytometric bead arra

61 cytokine concentrations, whereas increasing interleukin-10 concentrations.

62 individual cytokines showed that exposure to interleukin 10 could replicate this effect.

63 application, secreting human proinsulin and interleukin-10, cured 66% of mice with new-onset diabete

64 e footpad was associated with high levels of interleukin 10, decreased levels of interferon gamma, an

65 um induces pancolitis in colitis-susceptible interleukin-10-deficient mice and this phenotype require

66 ced immunosuppression is characterized by an interleukin-10-dependent elimination of dendritic cell b

67 ion, splenic natural killer cells induced an interleukin-10-dependent elimination of splenic dendriti

68 ammatory interleukin-6 and anti-inflammatory interleukin-10 during three distinct time periods after

69 ecrosis factor gene (TNF) G308A), rs1800890 (interleukin-10 gene (IL10) T3575A), rs6457327 (human leu

70 nin also triggered anti-inflammatory factors interleukin-10, heme oxygenase-1, and Hsp70 in macrophag

71 f the potent immunomodulatory cytokine human interleukin 10 (hIL-10).

72 f the potent immunomodulatory cytokine human interleukin 10 (hIL-10).

73 therapy; in serum, the ratio of IFN-gamma to interleukin 10 (IL-10) activity was decreased by 50%.

74 Individually, log10 mean concentrations of interleukin 10 (IL-10) and CXCL10 were significantly hig

75 ded early increases in Th2 cytokines such as interleukin 10 (IL-10) and IL-5 and late-stage increases

76 tobium-infected donors expressed cytoplasmic interleukin 10 (IL-10) and membrane-bound latency-associ

77 rus-specific T cells, elevated production of interleukin 10 (IL-10) and programmed death-1 (PD-1) the

78 killed spherules [FKS]) and for secretion of interleukin 10 (IL-10) and proinflammatory cytokines in

79 scular endothelial growth factor A (VEGF-A), interleukin 10 (IL-10) and prostaglandin E2 (PGE2) coope

80 ced smaller amounts of the immunosuppressive interleukin 10 (IL-10) and transforming growth factor be

81 function has been associated primarily with interleukin 10 (IL-10) because B-cell-derived IL-10 can

82 We found that interleukin 10 (IL-10) derived from CD4(+) regulatory T

83 The interleukin 10 (IL-10) family comprises cytokines struct

84 This was found to be the result of an interleukin 10 (IL-10) feedback mechanism, with endogeno

85 o be a potent inducer of human and murine DC interleukin 10 (IL-10) in vitro, a cellular event that w

86 Interleukin 10 (IL-10) is an anti-inflammatory cytokine

87 l coma score was associated with an elevated interleukin 10 (IL-10) level in serum specimens from HSV

88 erleukin 8, tumor necrosis factor alpha, and interleukin 10 (IL-10) production in 20 HIV-infected pat

89 Cell wall peptidoglycan stimulates interleukin 10 (IL-10) production in Staphylococcus aure

90 rginase activity, PD-1-PD-L1 expression, and interleukin 10 (IL-10) production.

91 dy and both interferon gamma (IFN-gamma) and interleukin 10 (IL-10) responses to the 42-kD C-terminal

92 netic polymorphisms in the anti-inflammatory interleukin 10 (IL-10) signaling pathway.

93 n gamma, interleukin 1beta, CCL5/RANTES, and interleukin 10 (IL-10) were elevated in RSV+ bronchiolit

94 ly, levels of the anti-inflammatory cytokine interleukin 10 (IL-10) were markedly elevated in monocyt

95 eukocytes, gamma interferon (IFN-gamma), and interleukin 10 (IL-10) were significantly reduced in inf

96 mor necrosis factor-alpha, interferon-gamma, interleukin 10 (IL-10), and CXCL9.

97 expression of the anti-inflammatory cytokine interleukin 10 (IL-10), and decreasing that of the pro-i

98 IL-6, interferon gamma (IFN-gamma), interleukin 10 (IL-10), and gp120 levels were quantified

99 ess interferon gamma, more neutrophils, more interleukin 10 (IL-10), and increased M. tuberculosis nu

100 erleukin1beta, interleukin 2, interleukin 6, interleukin 10 (IL-10), and soluble CD14 compared with H

101 gland sonicate showed elevated production of interleukin 10 (IL-10), interleukin 13, interferon gamma

102 ted individuals, induced protein 10 (IP-10), interleukin 10 (IL-10), macrophage inflammatory protein

103 (n = 96), but CXCL10, interleukin 6 (IL-6), interleukin 10 (IL-10), tumor necrosis factor alpha, and

104 Studies with Foxp3-deficient and interleukin 10 (IL-10)-deficient mice demonstrated that

105 The frequencies of FoxP3+ CD4+ T cells and interleukin 10 (IL-10)-expressing CD4+ T cells were incr

106 Interleukin 10 (IL-10)-producing B cells (regulatory B c

107 The great majority of interleukin 10 (IL-10)-producing CD4(+) T cells were Fox

108 d activator whose expression is repressed by interleukin 10 (IL-10).

109 eg cells to produce the suppressive cytokine interleukin 10 (IL-10).

110 oxide production, and elevated synthesis of interleukin 10 (IL-10).

111 production of the immunosuppressive cytokine interleukin 10 (IL-10).

112 ion of the potent anti-inflammatory cytokine interleukin 10 (IL-10).

113 plasma levels of anti-inflammatory cytokine interleukin 10 (IL-10).

114 tensity of interleukin 4 (IL-4; P < .05) and interleukin 10 (IL-10; 1440 vs 1273; P < .05).

115 tozoan parasite Leishmania mexicana requires interleukin-10 (IL-10) and FcgammaRIII (an activating Ig

116 Monogenic interleukin-10 (IL-10) and IL-10 receptor (IL-10R) defic

117 genic mutant null for VacA, strongly induced interleukin-10 (IL-10) and IL-6 production by human peri

118 ther immunosuppressive pathways, such as the interleukin-10 (IL-10) and programmed death 1 (PD-1) pat

119 n response to the immune regulatory cytokine interleukin-10 (IL-10) and regulatory T cells.

120 Treatment of donor corneas with interleukin-10 (IL-10) and transforming growth factor-be

121 hibition of MIP-2 and KC expression involved interleukin-10 (IL-10) and, to a lesser extent, IL-4 and

122 Interleukin-1b (IL-1b) and interleukin-10 (IL-10) biomarkers are one of many antige

123 i-Bordetella antibody levels and inducing an interleukin-10 (IL-10) cell-mediated response, likely co

124 Interleukin-10 (IL-10) curtails immune responses to micr

125 ibitor demonstrate a significant increase of interleukin-10 (IL-10) gene expression, which indicates

126 Interleukin-10 (IL-10) has been implicated in susceptibi

127 Although gamma interferon (IFN-gamma) and interleukin-10 (IL-10) have been shown to be critically

128 We investigated the role of interleukin-10 (IL-10) in cutaneous and pulmonary infect

129 sts a role for the immunomodulatory cytokine interleukin-10 (IL-10) in hepatitis C virus (HCV)-specif

130 wing that B1a cells secreted a high level of interleukin-10 (IL-10) in response to C. burnetii infect

131 or rapid secretion of virus-specific IgM and interleukin-10 (IL-10) in response to infection.

132 Interleukin-10 (IL-10) is a key immune-suppressive cytok

133 Interleukin-10 (IL-10) is a key immunoregulatory cytokin

134 Interleukin-10 (IL-10) is a pleiotropic anti-inflammator

135 Interleukin-10 (IL-10) is an immunomodulatory cytokine t

136 E. coli from ex-germfree wild-type (WT) and interleukin-10 (IL-10) knockout (KO) (IL-10(-/-)) mice s

137 udies in mice indicate that increased plasma interleukin-10 (IL-10) levels play an important role in

138 Treg cell and interleukin-10 (IL-10) levels remained elevated in the l

139 chronic malaria is associated with elevated interleukin-10 (IL-10) levels.

140 ial survival in vivo and reduced gallbladder interleukin-10 (IL-10) levels.

141 ion, while alternative activation of MDMs by interleukin-10 (IL-10) or LPS-plus-IL-1beta treatment si

142 es inhibitory networks, such as the PD-1 and interleukin-10 (IL-10) pathways, that impair immunity an

143 Interleukin-10 (IL-10) plays an important role in a host

144 Interleukin-10 (IL-10) plays an important role in the su

145 stemic reinfection is associated with robust interleukin-10 (IL-10) production and impaired protectiv

146 Interleukin-10 (IL-10) production and the percentage of

147 and benign T cells leading to Stat3-mediated interleukin-10 (IL-10) production by the malignant T cel

148 otably, lactate-grown C. albicans stimulated interleukin-10 (IL-10) production while decreasing IL-17

149 t triggered higher inflammatory cytokine and interleukin-10 (IL-10) production, a delayed gammadelta

150 differentiation to plasma cells, as well as interleukin-10 (IL-10) production, both of which are dep

151 athways, which subsequently led to a reduced interleukin-10 (IL-10) production.

152 creened the gamma interferon (IFN-gamma) and interleukin-10 (IL-10) responses to 6 HCMV peptide pools

153 Purpose Interleukin-10 (IL-10) stimulates the expansion and cyto

154 ascular endothelial growth factor (VEGF) and interleukin-10 (IL-10) than MSCs homing to non-pFUS-trea

155 patients induces a rapid increase in plasma interleukin-10 (IL-10) to levels that are significantly

156 in vitro cargo release kinetics and cellular interleukin-10 (IL-10) transgene transfection.

157 ates inflammation, the beneficial effects of interleukin-10 (IL-10) were further examined in leptin-d

158 inhibits the induction of anti-inflammatory interleukin-10 (IL-10), a phenotype effectively reversed

159 The biological function of interleukin-10 (IL-10), a pleiotropic cytokine with an e

160 of secreting the immunosuppressive cytokine interleukin-10 (IL-10), although in vivo CD8(+) T cell d

161 igh concentrations of lung tissue-associated interleukin-10 (IL-10), an anti-inflammatory and immunos

162 Interleukin-10 (IL-10), an important immunomodulatory cy

163 nterferon (IFN-gamma), interleukin-6 (IL-6), interleukin-10 (IL-10), and complement factor H was unaf

164 e secretion of interferon-gamma (IFN-gamma), interleukin-10 (IL-10), and transforming growth factor-b

165 he NF-kappaB-dependent cytokines, IFN-gamma, interleukin-10 (IL-10), IL-1beta, IL-6, and tumor necros

166 Through the production of interleukin-10 (IL-10), IL-35, and transforming growth f

167 ines including interferon-gamma (IFN-gamma), interleukin-10 (IL-10), IL-6, and IL-1 are produced in r

168 DR in NLCs as well as increased secretion of interleukin-10 (IL-10), indicating an altered inflammato

169 tumor necrosis factor alpha (TNF-alpha) and interleukin-10 (IL-10), two cytokines strongly implicate

170 xpress the potent immunosuppressive cytokine interleukin-10 (IL-10), which is not inherently produced

171 demand hematopoiesis in part by induction of interleukin-10 (IL-10)- and IL-27-mediated mechanisms.

172 Immune-mediated pathology in interleukin-10 (IL-10)-deficient mice during blood-stage

173 t Ehrlichia muris infection in wild-type and interleukin-10 (IL-10)-deficient mice.

174 enous replacement therapy induced a complex, interleukin-10 (IL-10)-dependent, antigen-specific syste

175 Interleukin-10 (IL-10)-producing B cells (B10 cells) pla

176 We hypothesized that naturally occurring, interleukin-10 (IL-10)-producing Bregs maintain toleranc

177 Interleukin-10 (IL-10)-producing regulatory B (Breg) cel

178 sorders has identified a functional group of interleukin-10 (IL-10)-producing regulatory B cells (Bre

179 ing levels of the anti-inflammatory cytokine interleukin-10 (IL-10).

180 expression of the anti-inflammatory cytokine interleukin-10 (IL-10).

181 production of the anti-inflammatory cytokine interleukin-10 (IL-10).

182 ls to secrete the anti-inflammatory cytokine interleukin-10 (IL-10).

183 xcessive immune responses via the release of interleukin-10 (IL-10).

184 modulation by the anti-inflammatory cytokine interleukin-10 (IL-10).

185 d histopathological effects are regulated by interleukin-10 (IL-10).

186 tain a higher frequency of B cells producing interleukin-10 (IL-10).

187 a significant increase of the expression of interleukin-10 (IL-10).

188 ered via the local and sustained delivery of interleukin-10 (IL-10; anti-inflammatory) and anti-trans

189 and chemokine (gamma interferon [IFN-gamma], interleukin 10 [IL-10], IL-13, IL-6, granulocyte-macroph

190 (tumor necrosis factor alpha [TNF-alpha] and interleukin-10 [IL-10]), BMMs were transfected with sele

191 nical malaria (gamma interferon [IFN-gamma], interleukin-10 [IL-10], and tumor necrosis factor alpha

192 cell (Treg) percentages; and interleukin 6, interleukin 10, IL-17A, interleukin 22, interleukin 23,

193 Exposure of Interleukin 10 (il10)-deficient mice to cigarette smoke

194 Models of interleukin-10 (Il10) and matrix metalloproteinase 8 (Mm

195 Interleukin-10 (IL10) overproduction (P = .0003) was fou

196 We have previously shown that interleukin-10 (IL10) suppresses pressure overload-induc

197 of the cardinal anti-inflammatory cytokine, interleukin-10 (IL10).

198 of the rhesus cytomegalovirus-encoded viral interleukin-10 immune-modulating protein.

199 his work, we showed that the main sources of interleukin 10 in peripheral blood mononuclear cells (PB

200 ministered lentiviral vector encoding murine interleukin-10 in altering the onset and relapse of dext

201 ature" comprising interferon (IFN)-gamma and interleukin-10 in T1D patients and IFN-gamma in siblings

202 65370-575 and the anti-inflammatory cytokine interleukin-10 in the gut.

203 response as modelled by an interleukin-6 and interleukin-10 interaction term was not (relative risk,

204 her in ZIKV-infected patients, and levels of interleukin 10, interferon gamma-induced protein 10 (IP-

205 otential control of HIV infection, including interleukin 10, interleukin 13, and interleukin 22.

206 interleukin-5, interleukin-6, interleukin-9, interleukin-10, interleukin-12, interleukin-13, tumor ne

207 (tumor necrosis factor-alpha, interleukin-6, interleukin-10, interleukin-12, interleukin-17) at day 1

208 leukin-8/CCL8) and cytokines (interleukin-6, interleukin-10, interleukin-17, granulocyte-macrophage c

209 rleukin-1beta, interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis facto

210 Interleukin-6, interleukin-8, interleukin-10, interleukin-18, and tumor necrosis facto

211 twork suggested that post-spinal cord injury interleukin-10 is driven by inducible protein-10, wherea

212 expression of the anti-inflammatory cytokine interleukin 10, it did not strongly contribute to the ab

213 L-10) and Latency-associated cytomegalovirus interleukin 10 (LAcmvIL-10) (collectively vIL-10) are ex

214 The reduction of the interleukin-10 level in natural killer cells by hydrocor

215 , whereas HBV coinfection and higher pre-ART interleukin 10 levels are associated with hepatitis flar

216 beta and interferon gamma levels, and higher interleukin 10 levels than PFCE-air-treated HbSS mice.

217 rrelated positively with Leishmania-specific interleukin 10 levels, negatively with Leishmania-specif

218 ; increased serum interleukin 6, CXCL10, and interleukin 10 levels; increased neutrophil counts; and

219 Interleukin-6 and interleukin-10 levels were both independently associated

220 feron-gamma, CXCL12, XCL1, interleukin-6 and interleukin-10 levels.

221 dependent response and favoring a macrophage interleukin-10-like phenotype.

222 mice with muscle-specific overexpression of interleukin-10 (M(IL10)).

223 al lesion, whereas a robust monocyte-derived interleukin 10-mediated profile is observed in children

224 ighted the role of the type I interferon and interleukin 10-mediated responses.

225 Interleukin-10-mediated regenerative postnatal tissue re

226 mainly produced by CD4(+)CD25(-) cells, and interleukin 10 messenger RNA expression was associated w

227 rs with human AAT resulted in an increase in interleukin-10 messenger RNA and CD8(+)CD11c(+)CD205(+)

228 or alpha-positive/negative (TNF-alpha(+/-)), interleukin-10-negative (IL-10(-)) cells and low numbers

229 -gamma, whereas most healthy donors produced interleukin-10 only.

230 encies of natural regulatory T cells but not interleukin 10 or transforming growth factor beta.

231 e not consistently different between groups (interleukin 10) or higher (tumor necrosis factor-alpha a

232 ed positive for tumor necrosis factor alpha, interleukin 10, or interleukin 6 production by HBV surfa

233 r-alpha, p = 0.003; interleukin-6, p = 0.01; interleukin-10, p = 0.005), and acute kidney injury when

234 matory (interleukin-8) to anti-inflammatory (interleukin-10) plasma cytokine levels was greater in pa

235 evels of specific gamma interferon-positive, interleukin-10-positive T cells, which protect animals f

236 oantibody-positive) and partially regulated (interleukin-10-positive, pauci-autoantibody-positive) re

237 CL had increased frequencies of circulating interleukin 10-producing CD4(+)CD25(-)CD127(-/low) cells

238 tively activated [ie, CD163(+)] macrophages, interleukin 10-producing cells, and transforming growth

239 of interferon gamma, reduced the numbers of interleukin 10-producing T cells, and increased neutroph

240 on, patients with AAH had greater numbers of interleukin 10-producing T cells, and reduced levels of

241 sion of naturally occurring Foxp3(+) CD25(+) interleukin-10-producing antigen-specific regulatory T c

242 ed lymphocytes were generated by coculturing interleukin-10-producing dendritic cells obtained from h

243 A restoration of interleukin 10 production by peripheral B cells was obse

244 Galectin-3 enhanced monocyte interleukin 10 production to a TLR2/1 ligand, whereas in

245 arrying the TLR1 80R-allele showed increased interleukin 10 production with C. burnetii exposure.

246 ma and interleukin 17 production and lack of interleukin 10 production, a pro-inflammatory profile.

247 tibility to Leishmania infection, mainly via interleukin 10 production.

248 ion, which was associated with a decrease in interleukin-10 production by hepatic T cells and a more

249 C resulted in higher interleukin-6 and lower interleukin-10 production by lipopolysaccharide-stimulat

250 cutaneous inflammatory responses induces of interleukin-10 production in dendritic cells and priming

251 mor necrosis factor-alpha, nitric oxide, and interleukin-10 production.

252 lated M1 polarization through stimulation of interleukin-10 production.

253 Although both interleukin-6 and interleukin-10 productions are associated with death, th

254 eline [interleukin-6] and [interleukin-6] x [interleukin-10] profiles, whereas patients with the lowe

255 and interferon gamma (r = 0.562, P = .005), interleukin 10 (r = 0.453, P = .03), and sCD27 secretion

256 C-reactive protein (r = -0.70, P = 0.0006), interleukin-10 (r = -0.59, P = 0.007), and interleukin-6

257 The interleukin-6/interleukin-10 ratio directly correlated with plasma lac

258 al intracellular tumor necrosis factor-alpha/interleukin-10 ratio than that of mature neutrophils, su

259 ange complexes and a lower interleukin-1beta/interleukin-10 ratio than the control group (P < 0.05).

260 g 248S produce a lower tumor necrosis factor/interleukin-10 ratio when stimulated with Mycobacterium

261 Infants with defects in the interleukin 10 receptor (IL10R) develop very early onset

262 SELEX experiment developing aptamers against Interleukin 10 receptor alpha chain (IL-10RA) and experi

263 Interleukin 6, interleukin 10 receptor alpha subunit, colony stimulatin

264 Interleukin-10 receptor (IL-10R) signaling is considered

265 Intact interleukin-10 receptor (IL-10R) signaling on effector a

266 ges, stimulated M1 macrophage activation and interleukin 10 release, and decreased tumor necrosis fac

267 ot affecting tumor necrosis factor-alpha and interleukin-10 release).

268 6 hours but had normalized by day 2, whereas interleukin-10 remained persistently elevated and high-d

269 For TLR1, increased interleukin 10 responses to C. burnetii in individuals c

270 T-cell proliferative, interferon gamma, and interleukin 10 responses to HBV, with increased frequenc

271 ntiviral vector-mediated local expression of interleukin-10 resulted in significantly increased level

272 s (CD4+, CD25+, and FoxP3+) and its cytokine interleukin 10, resulting in downregulation of T effecto

273 ically-delivered lentiviral vectors encoding interleukin-10 safely penetrated local mucosal tissue an

274 Defects in interleukin-10 signaling have a Mendelian inheritance pa

275 on, including JAK/Stat signaling pathway and interleukin-10 signaling pathway.

276 persist due to upregulation of the cellular interleukin-10 signaling pathway.

277 We found that levels of interleukin-6 and interleukin-10, specific markers of cardiac remodeling (

278 feration of fibroblast-like synoviocytes and interleukin-10 synthesis in macrophages each partially c

279 ediated boosting of antibody titers to viral interleukin-10, there was modest evidence for increased

280 founding variables by multivariate analysis, interleukin-10/tissue necrosis factor ratio at 72 hours

281 Sustained elevation of interleukin-10/tissue necrosis factor ratio at 72 hours

282 ation and production of interferon gamma and interleukin 10) to overlapping hepatitis B virus (HBV) p

283 ed expression of mannose receptor-1 (CD206), interleukin-10, transforming growth factor-beta, arginas

284 here is accumulating evidence that the viral interleukin-10 (vIL-10) ortholog of both human and rhesu

285 Also, in CL lesions, interleukin 10 was mainly produced by CD4(+)CD25(-) cell

286 that the parasite-driven regulatory cytokine interleukin-10 was exclusively coming from the intermedi

287 Circulating interleukin-10 was significantly elevated in thoracocerv

288 ther with production of interferon gamma and interleukin 10, was also detected in the lesions.

289 atory cytokines, including interleukin-6 and interleukin-10, was diminished in trained compared to un

290 Meanwhile, regulatory cytokine, interleukin-10, was enhanced.

291 Higher levels of alanine transaminase and interleukin 10 were also associated with hepatitis flare

292 Plasma levels of interleukin-6 and interleukin-10 were 290 and 166 pg/mL and decreased at a

293 reporter genes firefly-luciferase and murine interleukin-10 were administered by intrarectal instilla

294 eukin-6, interleukin-8, interleukin-17A, and interleukin-10 were measured by enzyme-linked immunosorb

295 or necrosis factor-alpha, interleukin-6, and interleukin-10 were observed 5 hours after cecal ligatio

296 necrosis factor alpha, gamma interferon, and interleukin-10 were upregulated in infected mice.

297 s, as well as an anti-inflammatory cytokine (interleukin-10), were reduced in the lungs of vaccinated

298 tokines (C-X-C motif chemokine ligand 10 and interleukin 10), which correlated with populations of in

299 production of the anti-inflammatory cytokine interleukin 10 while inhibiting B-cell expression of pro

300 specific CD4(+) T-cells in children produced interleukin 10, while responses in adults were dominated